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Abstract
The Minimum Information for Biological and Biomedical Investigations (MIBBI) project provides
a resource for those exploring the range of extant minimum information checklists and fosters
coordinated development of such checklists.
To fully understand the context, methods, data and conclusions that pertain to an experiment,
one must have access to a range of background information. However, the current diversity of
experimental designs and analytical techniques complicates the discovery and evaluation of
experimental data; furthermore, the increasing rate of production of those data compounds the
problem. Community opinion increasingly favors that a regularized set of the available
metadata (‘data about the data’) pertaining to an experiment1,2 be associated with the results,
making explicit both the biological and methodological contexts. Many journals and funding
agencies now require that authors reporting microarray-based transcriptomics experiments
comply with the Minimum Information about a Microarray Experiment (MIAME) checklist3
as a prerequisite for publication4–7. Similarly, minimum information guidelines for reporting
proteomics experiments and describing systems biology models are gaining broader support
in their respective database communities8,9; and progress is being made toward the
standardization of the reporting of clinical trials in the medical literature10. Such minimum
information checklists promote transparency in experimental reporting, enhance accessibility
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to data and support effective quality assessment, increasing the general value of a body of work
(and the competitiveness of the originators).
Collaborative minimum information checklist development projects for diverse biologically
and technologically delineated subject areas are ongoing. A special issue of the journal
OMICS11 included invited pieces from eight communities supporting minimum information
checklist development projects. However, until recently there were no mechanisms for such
projects to coordinate their development. Consequently, the full range of checklists can be
difficult to establish without intensive searching, and tracking their evolution is nontrivial.
Furthermore, overlaps in scope and arbitrary decisions on wording and substructuring inhibit
their use in combination. These issues present difficulties for checklist users, especially those
who routinely combine information from several disciplines. Here we explore some of the
issues arising from the development of checklists in relative isolation, discuss the potential
benefits of greater coordination and describe the mechanisms we have put in place to facilitate
such coordination. In summary, we present the MIBBI project (http://www.mibbi.org/), which
maintains a web-based, freely accessible resource for checklist projects, providing
straightforward access to extant checklists (and to complementary data formats, controlled
vocabularies, tools and databases), thereby enhancing both transparency and accessibility, as
discussed above. MIBBI is managed by representatives of its various participant communities
and is fully open to comment from any interested party. Our goal is to facilitate the development
of an integrated checklist resource site for the wider bioscience community.
On the need to harmonize minimum information checklists
The current proliferation of documents specifying the minimum information to provide when
reporting particular kinds of experimental data has in large part been driven by the advent of
a range of so-called ‘omics’ (and allied) technologies, many of which operate in a high-
throughput mode, thereby generating large volumes of data. These documents have been
developed independently for the most part, and as a result feature many arbitrary differences
in both wording and structure. This greatly complicates the integration of data sets that comply
with different minimum information checklists. Increasing appreciation of the potential value
accruing to ‘secondary use’ of data is also a significant factor8, reflecting the general increase
in frequency of data-driven (as opposed to hypothesis-driven) investigations in recent years.
These trends have together made the need for coordination and harmonization between groups
developing data format and reporting standards a critical issue10. Throughout this document,
the words ‘standard’ and ‘standardization’ are used to refer only to the regularization of data
capture, representation, annotation or reporting, as opposed to best practices for experimental
procedures. Specifically, we refer to three kinds of reporting standards: (i) minimum
information checklists or guidelines; (ii) formats (syntax); and (iii) controlled vocabularies and
ontologies (semantics).
It is clear that checklists should be developed through close consultation with their sponsoring
practitioner communities, but such checklists should also, we believe, be designed to anticipate
‘cross-domain’ integrative activities. It is unhelpful to confine checklists for the use of
particular technologies to a limited set of biologically delineated communities, or to conceive
of any such community as being restricted to a particular set of technologies. Consider mass
spectrometry, which is used in the study of proteins, metabolites and even to sequence genes;
or consider toxicology, which may use any or all of the available ‘omics’ technologies in pursuit
of the greater understanding of the mode of action of a particular compound. Clearly the vistas
from any two locations can overlap substantially, so who can claim sole ownership of any part
of the scientific landscape? Initiatives such as that to harmonize the description of ‘sample’ (the
biological source material for a study)12 or to develop (separable) community-level extensions
to shared core standards such as MIAME to better describe domain-specific studies (for
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example, in environmental biology13) are clearly the order of the day. This throws into relief
an important division between analytical approaches and the various subdivisions of the
biosciences. Checklists that do not span that division will always achieve greater utility because
they can be reused more straightforwardly to construct new, made-to-order checklists for a
wider range of workflows.
Box 1
Checklist development projects registered with MIBBI
CIMR (http://msi-workgroups.sourceforge.net/)
The Metabolomics Standards Initiative’s Core Information for Metabolomics Reporting
(CIMR) comprises modules for particular aspects of metabolomics workflows; various
biological disciplines (for example, microbiology, mammalian biology, plant biology);
analytical techniques such as chromatography and NMR; and the use of various statistical
techniques.
MIACA (http://miaca.sourceforge.net/)
The Minimum Information About a Cellular Assay (MIACA) checklist relates to the
perturbation of cells with various classes of molecule, such as small interfering RNA
(siRNA) or small chemical compounds. It also provides guidance on the representation of
environmental stressors such as temperature shift or starvation, and combinations thereof.
MIAME (http://www.mged.org/Workgroups/MIAME/miame.html)
The Microarray and Gene Expression Data Society’s well-established Minimum
Information About a Microarray Experiment (MIAME) checklist relates to the use of
(micro)arrays (most commonly to assay messenger RNA abundance) and analysis of the
data generated.
MIAME/Nutr (http://www.mged.org/Workgroups/rsbi/rsbi.html)
MIAME/Tox (http://www.mged.org/Workgroups/rsbi/rsbi.html)
MIAME/Env (http://nebc.nox.ac.uk/miame/miame_env.html)
MIAME/Plant (http://miame-plant.sourceforge.net/)
The MIAME checklist has recently been extended to capture parameters appropriate to
nutrigenomics (/Nutr), toxicogenomics (/Tox), environmental biology (/Env) and
phytology (/Plant), in each case adding relevant information about the background to the
experiment.
MIAPA (http://www.mibbi.org/index.php/projects/MIAPA)
The Minimum Information About a Phylogenetic Analysis (MIAPA) checklist relates to
the use of software to align biological sequences, and the subsequent use of algorithms to
construct phylogenies or cladograms and to draw inferences from them.
MIAPE (http://www.psidev.info/miape/)
The Minimum Information About a Proteomics Experiment (MIAPE) checklist comprises
modules for reporting the use of and the interpretation of data from various analytical
techniques, such as mass spectrometry, gel electrophoresis or liquid chromatography.
Modules addressing the description of the biological material under study are planned.
MIARE (http://www.miare.org/)
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The Minimum Information About an RNA interference Experiment (MIARE) checklist
identifies minimal reporting parameters for aspects of high-throughput RNA interference
(for example, siRNA and small hairpin RNA) screens, usually in conjunction with cellular
assays (compare MIACA checklist, above) and flow cytometry (compare MIFlowCyt
checklist, next).
MIFlowCyt (http://flowcyt.sourceforge.net/)
The Minimum Information for a Flow Cytometry Experiment (MIFlowCyt) checklist
addresses the use of flow cytometry, especially to measure the phenotype and function of
cells; information is required about the sample analyzed; the probe, fluorochrome and
instrument used; and the analysis of the data collected.
MIGen (http://www.mibbi.org/index.php/projects/MIGen)
The Minimum Information about a Genotyping experiment (MIGen) checklist addresses
genotyping based on single-nucleotide and microsatellite-repeat polymorphisms, and
genetic association and linkage analysis in humans, with special reference to immunology.
MIGS/MIMS (http://gensc.org/)
The Minimum Information about a Genome Sequence (MIGS) checklist is an extension of
the metadata traditionally captured by the International Nucleotide Sequence Databases
(DDBJ, EMBL and GenBank). It captures information relating to nucleic acid sequence,
location and sequencing method. The description of habitat is also being extended by means
of the tightly integrated Minimum Information About a Metagenomic Sequence/Sample
(MIMS) checklist.
MIMIx (http://www.psidev.info/)
The Minimum Information required for reporting a Molecular Interaction experiment
(MIMIx) checklist includes the identity of molecules that participate in an interaction (with
accession number), the methods by which both the interaction and the identity of the
participants were established and the role of these molecules in the context of the experiment
(as distinct from their biological role).
MIMPP (http://www.interphenome.org/)
The Minimum Information for Mouse Phenotyping Procedures relates to the diverse
protocols used to characterize the phenotype of a mouse. The checklist addresses both
behavioral and physiological traits.
MINI (http://carmen.org.uk/standards/)
The Minimum Information about a Neuroscience Investigation (MINI) checklist identifies
the minimum information required to report the use of electrophysiology in a neuroscience
study.
MIQAS (http://miqas.sourceforge.net/)
The Minimum Information for QTLs and Association Studies (MIQAS) checklist relates
to the mapping of quantitative trait loci (QTLs) and their association with genetic markers.
MIqPCR (http://www.rdml.org/)
The Minimum Information about a Quantitative Polymerase Chain Reaction experiment
checklist addresses the minimal reporting parameters for experiments involving quantitative
PCR.
MIRIAM (http://biomodels.net/miriam)
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The Minimum Information Requested In the Annotation of biochemical Models (MIRIAM)
checklist offers formal requirements for describing theoretical models of biochemical
systems.
MISFISHIE (http://mged.sourceforge.net/misfishie/)
The Minimum Information Specification For In Situ Hybridization and
Immunohistochemistry Experiments (MISFISHIE) checklist21 addresses visual
interpretation–based tissue gene expression localization experiments, such as those using
in situ hybridization or immunohistochemistry.
STRENDA (http://www.strenda.org/)
The Standards for Reporting Enzymology Data (STRENDA) initiative, along with
participants in the biannual ESCEC (Experimental Standard Conditions of Enzyme
Characterizations) symposia, maintain a series of checklists addressing the description of
enzymatic activity data and the experiments in which these data were collected. These
checklists are subject to permanent review by the community involved.
The management of information from experiments (both data and metadata) requires the
adoption of reporting standards that ensure transparency and interoperability and that facilitate
the integration and exchange of data from different sources. Reporting standards also facilitate
the execution of more powerful queries against repositories of experimental data because core
information will be regularized and extended information will be supplied in a well
characterized manner. This long-term vision will require significant effort and buy-in from a
range of scientific communities spread across many nations, but development of some of the
kinds of component required to establish such infrastructure is well underway: Functional
Genomics Experiment14 (FuGE) is an object-oriented data model (with an associated XML-
based syntactic format) capable of capturing a wide range of (meta)data in a consistent manner;
Reporting Structure for Biological Investigations (RSBI)15 provides a foundational lingua
franca for standards projects (described further below) and builds on this to define a simple,
but general, tabular format (ISA-TAB)16 aligned with FuGE; Ontology for Biomedical
Investigations (OBI; http://obi.sourceforge.net/) is a broad-scope ontology providing a self-
compatible set of terms with which to describe a wide range of biological and medical studies;
and the Open Biomedical Ontologies (OBO) Foundry17 (http://obofoundry.org/) coordinates
the development of a set of ‘gold-standard reference ontologies’ (including OBI) that can be
used in combination because they are based on common principles and, importantly, because
procedures have been established to ensure resolution of the conflicts that might arise where
ontologies overlap.
Although the primary purpose of minimum information checklists is to guide researchers in
reporting their experiments, they can, for the kinds of projects mentioned above, serve a
valuable role as key ‘use cases’, in that they represent the distilled opinion of a particular
community on the information that should normally be captured to effectively describe a
particular kind of experiment. They therefore provide a realistic scenario with which to test
any resource’s suitability for use by a community; for example, for software and database
developers to ensure that their products can handle the specified data appropriately; or for
instrument vendors to offer checklist-compliant data set export from their instrument
management software. It is also likely that journals and funders will adopt some checklists
wholesale, incorporating them into their guidance for authors and applicants.
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A resource for minimum information checklists: MIBBI
The activities of standardization groups often go unpublished and may not be accessible at all,
practically speaking. A common resource for minimum information checklists, coordinated by
a group of community representatives from ongoing standardization activities, will help unify
the standardization community. It will assist in recruiting participants to ongoing activities and
it will help to maintain transparency of process by providing access to project-related
information (for example, status, key players and plans). It will also ease the establishment of
new initiatives by providing answers to questions such as, “How do we get started?” and,
importantly, “How do we make sure we don’t reinvent the wheel?”. Such an effort will improve
communication, knowledge transfer and integration between checklist development projects
hailing from different scientific communities and, further, between different kinds of reporting
standards projects, ultimately resulting in simplified access to a broad range of richly annotated
data for the end user. Thus, we have established the MIBBI project—a web-based, communal
resource designed to act as a ‘one-stop shop’ for those exploring the range of extant checklist
projects and to foster collaborative, integrative development of checklists
(http://www.mibbi.org/).
MIBBI has two key parts. The first is the ‘Portal’, which exists simply to raise awareness of,
and afford more straightforward access to, a wide range of checklists by providing researchers,
journal editors, reviewers, funders and the wider community of checklist developers with a
quick and simple way to discover (whether there is) a checklist addressing a particular area
and to establish the scope and progress of the underlying project. The Portal provides summary
information for each of the MIBBI-affiliated projects; specifically, the primary contact(s) and
website (where available), an overview of the project’s scope and developmental status and
links to publications and other documents (including, where possible, a link to the most recent
version of that project’s checklist). Information available through the Portal will be updated
as circumstances change (for example, if a project is fragmented or amalgamated, or simply
becomes dormant). Box 1 offers brief textual descriptions of the 21 projects currently registered
with MIBBI; Table 1 provides a representation of the concepts that comprise each project’s
scope, along with their checklist’s developmental status and, where applicable, an indication
that a checklist is composed of separate modules.
By signing up with the MIBBI Portal and thereby attracting more intensive peer oversight,
communities will come under pressure to maintain their checklists in light of scientific
advances, to provide open access to their processes and to respond to comments. We hope that
one of the primary benefits of the Portal will be to raise awareness in the biological and medical
communities of the importance of standardization, thereby increasing willingness among
researchers to become involved in guiding and shaping the evolution of these activities. We
hope it will help push the community to strive for compliance in their own publication and
data-dissemination practices by facilitating access to relevant information about these efforts.
We also see this as an excellent artifact with which to promote collaboration within and between
communities: the principle we endorse is that if a broadly relevant effort already exists (for
example, describing the use of a particular technology), individuals with an interest should
seek to join that effort rather than compete with it. However, it is crucial that MIBBI never
preclude revisions or innovations; the hoped-for kudos and enhanced coordination accruing to
membership should not translate to a possible dominion.
The second key part of MIBBI is the ‘Foundry’. Communities can, if motivated, sign up with
the Foundry to jointly examine ways to refactor the checklists over which they have control
and then to develop a suite of self-consistent, clearly bounded, orthogonal, integrable checklist
modules. These modules will then be made available to the community through the
MICheckout tool, a collaborative development between the European Bioinformatics Institute
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and the UK Natural Environmental Research Council’s Environmental Bioinformatics Centre.
MICheckout will assist users in compiling the correct list of modules and downloading them
in a form that they can use. Note that registering a project with MIBBI implies no commitment
by a project to participate in the Foundry activity. Furthermore, attempts to integrate checklists
through the Foundry should be managed through a community-driven mechanism that relies
primarily on openness and transparency to encourage (voluntary) uptake. The MIBBI Foundry
is modeled on the OBO Foundry17, a newly established initiative in the field of ontology
development. Communities working together through MIBBI will produce orthogonal (that is,
non-overlapping) minimum information modules, just as the communities involved with the
OBO Foundry are aiming to produce orthogonal ontologies.
Foundry activities must be driven by the member communities (acting through their
representatives). In preparation for the Foundry activity, we have established discussion forums
to facilitate communication between communities to encourage discussion of the overlaps
between checklists. Exploratory studies are ongoing, based on coarse comparison tables (such
as Table 1) that highlight areas addressed by one or more projects. The next stage is to use
‘groupware’ (that is, a wiki or an online document-sharing tool) to jointly develop modules for
those shared areas. Throughout this gradually intensifying activity, we will hold regular face-
to-face meetings that act as development workshops and promote good working relationships
between project representatives. The first such meeting was held in April 2008 at the European
Bioinformatics Institute and was funded by the UK’s Biotechnology and Biological Sciences
Research Council. This first meeting rapidly reached consensus on a work plan and established
working groups to begin to generate MIBBI Foundry modules. A full workshop report is
available through the project’s web-site (http://www.mibbi.org/).
High-level abstractions of the components of experimental workflows offer a useful framework
to support the integration of checklists. An example of a group attempting to produce such
abstractions is the RSBI working group14, which interacts with a number of other
initiatives18–20 in working toward an integrated view of functional genomics investigations.
In their characterization, an ‘Investigation’ is a self-contained unit of scientific enquiry, with
a holistic hypothesis or objective and a design that is defined by the relationships between one
or more ‘Studies’ and ‘Assays’. A Study represents the part of an experiment containing
information about the biological material, and an Assay is the part using particular technologies
that produce data. The RSBI’s proposed framework of well defined, high-level abstractions
(such as the three just described) was developed because the above concepts are duplicated,
but differently named, across different checklists, confounding the uniform description of the
diverse events that may occur within a Study (sensu RSBI).
Box 2
MIBBI methods
For the foundational analysis, we created a base data set (Table 1) by analyzing the content
of the registrant projects’ checklists and deriving the list of 65 concepts presented. These
concepts were created for the purpose of this analysis and are not taken from any other
source, although the meanings of ‘study’ and ‘assay’, where they appear, are as set by the
RSBI. The concepts have been designed to capture the content of a checklist in an intuitive
but compact manner, which means that some concepts represent a large body of methods
and technologies (for example, ‘nucleic acid sequencing’). However, where a component
of such a broad concept was found to have an analog in another project’s checklist, that
component was factored out to form a new standalone concept (for example, ‘detection/
tagging/staining’ is a concept common to workflows involving microarraying, gel
electrophoresis and mass spectrometry), the better to highlight the commonalities between
projects. Note also that some concepts are just ‘naturally’ narrow (such as ‘citations et
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cetera’, which addresses external referencing, for example, to published papers or to data
sets in repositories). The 65 ad hoc concepts thus derived have been used throughout the
analyses presented here. In some cases, concepts in Table 1 are indented; this is to indicate
that they represent a further specialization of the last less-indented concept above (for
example, a ‘human’ is an ‘animal’, which is a ‘generic organism’). However, the
specialization of a more general concept does not imply that those concepts’ content
overlaps as might be the case in an ontology (that is, ‘human’ cannot be taken to imply
‘animal plus additional information’), and having a specific requirement (for example,
‘human’) does not imply that there is also generic (that is, for any organism) guidance. The
concepts have been represented thus simply to guide the eye while demonstrating that a
project may address a concept in a generic or a specific manner, or may actually provide
both kinds of requirement (six projects do this, to varying degrees).
Foundational analysis of MIBBI-registered projects
To better understand the scope and depth of the various MIBBI-registered minimum
information checklists, we performed a comparative analysis. Table 1 presents a projection of
the various checklists onto a coarse-grained list of ad hoc concepts, constructed exclusively
for the purpose of identifying overlaps between those existing checklists; note that the concepts
vary widely in breadth of scope (see Box 2), so the number of concepts addressed by any one
project is not necessarily indicative of the size of that project’s guidelines, as some concepts
cover whole workflows (for example, ‘nucleic acid sequencing’). It will be clear to the reader
that some of these concepts, such as ‘organism’, are almost universal, whereas others, such as
‘quantitative PCR amplification’, may relate to one group alone. It is also clear that the depth
of description required in relation to particular concepts varies widely across projects,
suggesting a ‘tiered’ approach; that is, some of the checklist modules generated by the MIBBI
Foundry should, in some cases, require a different depth of description contingent on the
particular experimental context. Row and column totals (summing presence or absence only)
are provided in Table 1; the row totals have been used to rank-order concepts by ‘popularity’.
Figure 1 lists the eighteen most common ad hoc concepts.
To support greater understanding of the relatedness of the different projects and of the various
ad hoc concepts, we conducted two pairwise comparisons using the data presented in Table 1:
concepts ‘shared’ between pairs of projects, and pairs of concepts occurring together within
projects (counting presence or absence only). Supplementary Figure 1 online illustrates the
interrelatedness of the 21 MIBBI-registered projects both as a tree and as an interaction graph.
These two representations make clear that there is a subset of closely related (that is, heavily
overlapping) projects; these are, broadly speaking, the ‘technologically delineated’ projects,
such as MIAME and the Minimum Information About Proteomics Experiment (MIAPE). It is
also clear that there are many projects that are ‘related’ (according to the tree, if considered in
isolation) only by their low degree of relatedness to any other project (as the interaction graph
makes explicit). Supplementary Figure 2 online presents an unrooted tree expressing the
relatedness of individual concepts. Although this analysis is based on the various projects’
scopes, rather than any sense of the similarity of the concepts themselves, it produces some
sensible-looking groupings. All the highly ranked (‘high-priority’) concepts from Figure 1
cluster together because most of the projects share an interest in many of them, so they are
often found to occur together in individual projects’ scopes. Such an analysis can help in
deciding how the ad hoc concept-based survey presented in Table 1 should be used as we draft
the checklist modules that will ultimately be developed by participants in the MIBBI Foundry’s
activities (that is, whether some concepts can be combined, whether others should be further
subdivided, and so on).
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These various analyses make two things plain: first, that there are standout priority areas for
the MIBBI Foundry (for example, the uniform description of an organism); and second, that
there are many niche areas where little or no collaborative activity is required (for example,
the process of mouse phenotyping)—a simple endorsement by MIBBI of the products of a
particular project being sufficient, as things stand.
Conclusions
By providing easy access to checklist development projects and their products, MIBBI will
facilitate the discovery of checklists appropriate to the needs of practitioners from diverse parts
of biological and biomedical science (the ‘one-stop shop’ principle). The widespread
availability of well-annotated data sets, ensuant to the routine use of minimum information
checklists, will increase secondary use of data and allow for a more thorough assessment of
the worth of a body of work, making for more efficient and effective science.
MIBBI will increase connectivity between minimum information checklist projects and, more
widely, will increase connectivity with projects developing other kinds of informatics resources
(formats, vocabularies, tools, databases). The resultant evolution of an interdisciplinary
community of checklist developers will bring into focus the collective expertise residing in
that group. It will accelerate the establishment of mutually beneficial networks of expertise,
and it will advance (through the MIBBI Foundry, building on the foundational analysis
presented here) our long-term vision of a fully integrated, broad-coverage suite of minimum
information checklists, in step with the general movement in the biological and medical
sciences toward integrated, multifaceted investigations of the puzzles that remain to be
addressed in the postgenomic era.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
The eighteen highest-ranked ad hoc concepts, according to Table 1. This highlights priority
areas for the MIBBI Foundry (though the concepts used here may not directly translate into
guidelines modules).
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